WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Drug-induced liver injury (DILI)

Accurately predict drug-induced hepatotoxicity in early discovery


Hepatotoxicity remains a major cause of drug attrition, with existing in vitro and in vivo models failing to capture DILI responses.

Most medications are metabolized in the liver, which makes it one of the primary tissues affected by adverse drug reactions. Earlier identification means that promising drugs can undergo structural modifications to address toxicity issues to lower attrition rates. To do so requires preclinical assays with greater human relevance and sensitivity.

Our solution

Our Liver-on-a-chip DILI Assay allows you to predict human liver responses to acute and chronic drug exposure, in the presence/absence of underlying disease.

This in vitro assay consists of human primary liver parenchymal and non-parenchymal cells (NPCs) cultured in 3D under perfusion to form tissues from which it is possible to detect functional liver-specific endpoints (including clinical biomarkers such as albumin and ALT/AST). The assay enables the sensitive assessment of compound toxicity with full dose–response curves and, by incorporating Kupffer cells, allows for the evaluation of immune-mediated toxicity.

Both acute and chronic exposure to compounds can be assessed by comparing responses to single- and multi-dosed tissues for up to four weeks. The assay produces highly functional and metabolically active liver tissues for DILI screens to give deep mechanistic insights into the toxicity profile of a compound.

DILI cells

Studying DILI

Limitations with current techniques

  • Poor in vitro to in vivo translation
  • Fail to provide deep mechanistic insights into the cause of toxicity
  • Many advanced in vitro models are low throughput limiting the number of data points
  • Challenging to run chronic exposure assays
  • Production of toxic phase I and II metabolites is not possible

Advancements with PhysioMimix OOC®

  • Translate data from the lab to the clinic by using clinical biomarker reporting
  • Assess multiple cellular endpoints to determine the mechanism of toxicity
  • Generate full dose–response curves for multiple compounds per plate
  • Long-term liver cultures facilitate prolonged repeat dosing for weeks
  • Correlate the production of toxic phase I and II metabolites with cell health measurements

End point measurements


Longitudinal and endpoint measurements include (but not limited to):

Functionality biomarkers

  • Cytochrome P450 enzyme activity
  • Albumin production
  • Urea production

Clinical liver heath biomarkers

  • Lactose dehydrogenase (LDH) release
  • Adenosine Triphosphate (ATP)
  • Aspartate Transferase (AST)/Alanine amino transferase (ALT)

Optional profiling analysis

  • Quantitative PCR
  • Transcriptomics

Generate high content data for a complete DILI profile


Our sensitive DILI assay provides high-content data from every replicate allowing the exploration of mechanisms of DILI alongside the assessment of a range of cell health markers.

Rowe et al., 2018

DILI profile pie chart
DILI assay graph

​

​

Improve in vitro to in vivo translation


Improved data translatability from the lab to the human is achieved through full dose–response experiments measuring clinical markers, such as ALT/AST, and has been tested using a range of toxic therapeutics.

Improved in vitro to in vivo translation line grpahs
figure app dili2 v2 |

Access our DILI Service


Get instant access to the PhysioMimix DILI Assay via our CRO Service. Through a collaborative approach, our experts work with you to plan and execute your study.

Standard and bespoke projects are carried out by our dedicated team of scientists in our CRO facility providing you with actionable data within weeks.

Learn more

Add PhysioMimix OOC into your lab


Harness the power of PhysioMimix OOC in your own lab with the purchase of a single- or multi-organ microphysiological system.

With a growing community of users and support from our experts, there has never been a better time to transition into 3D cell culture.

Learn more

Featured resources

Application notes

New AppNOTE |

Human liver microphysiological system for predicting the drug-induced liver toxicity of differing drug modalities

Application notes

MPS Fatty Liver graphic |

Microphysiological system for studying fatty liver disease and its impact on drug-induced liver injury

Blogs

blog lung in crisis |

De-risking drug-induced liver injury through the predictive power of organ-on-a-chip

View all Drug-induced liver injury Service related resources

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023